Quest Diagnostics EBITDA 2010-2024 | DGX

Quest Diagnostics EBITDA for the quarter ending June 30, 2024 was $0.472B, a 2.61% increase year-over-year.

  • Quest Diagnostics 2023 EBITDA was 1.701B, a 8.79% decline from 2022.
  • Quest Diagnostics 2022 EBITDA was 1.865B, a 33.13% decline from 2021.
  • Quest Diagnostics 2021 EBITDA was 2.789B, a 19.6% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Quest Diagnostics EBITDA 2010-2024 | DGX

  • Quest Diagnostics 2023 EBITDA was 1.701B, a 8.79% decline from 2022.
  • Quest Diagnostics 2022 EBITDA was 1.865B, a 33.13% decline from 2021.
  • Quest Diagnostics 2021 EBITDA was 2.789B, a 19.6% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Fresenius SE (FSNUY)$21.4B
DaVita (DVA)$13.8B
Encompass Health (EHC)$9.2B
Chemed (CHE)$8.7B
Elanco Animal Health (ELAN)$7.1B
Option Care Health (OPCH)$5.3B
RadNet (RDNT)$4.9B
Amedisys (AMED)$3.2B
Astrana Health (ASTH)$2.7B
LifeStance Health (LFST)$2.6B
Addus HomeCare (ADUS)$2.4B
U.S Physical Therapy (USPH)$1.3B
Pennant (PNTG)$1B
Aveanna Healthcare Holdings (AVAH)$1B
Atai Life Sciences (ATAI)$215M
Daxor (DXR)$46M
ATI Physical Therapy (ATIP)$26M
MEDIROM Healthcare Technologies (MRM)$19M
Psychemedics (PMD)$14M
Ontrak (OTRK)$10M
Novo Integrated Sciences (NVOS)$5M
IMAC Holdings (BACK)$2M